Subsequent Events	12 Months Ended
Mar. 31, 2026
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On April 23, 2026, the Company received a CRL from the FDA in response to their NDA for GTx-104. The CRL referenced certain items related to the chemistry, manufacturing, and controls (CMC) and other non-clinical sections of the application, including items related to additional leachable data time points for commercial product, non-clinical product toxicology risk assessments, and cGMP deficiencies at their CMO. A Type A meeting with the FDA has been scheduled to potentially clarify the path forward and determine the appropriate next steps. In order to prioritize resolving the items cited in the FDA’s CRL, the Company does not plan to resume internal development funding for GTx-102 or GTx-101 under its current operating plan. Accordingly, the Company determined that the remaining carrying value of the GTx-102 and GTx-101 IPR&D assets of $9,196 and $4,337, respectively, are no longer recoverable on an internal-development basis. The Company expects to recognize an impairment charge for the full remaining carrying value in the first quarter of fiscal year 2027.

Subsequent Events

12 Months Ended

Mar. 31, 2026

13. Subsequent Events

On April 23, 2026, the Company received a CRL from the FDA in response to their NDA for GTx-104. The CRL referenced certain items related to the chemistry, manufacturing, and controls (CMC) and other non-clinical sections of the application, including items related to additional leachable data time points for commercial product, non-clinical product toxicology risk assessments, and cGMP deficiencies at their CMO. A Type A meeting with the FDA has been scheduled to potentially clarify the path forward and determine the appropriate next steps. In order to prioritize resolving the items cited in the FDA’s CRL, the Company does not plan to resume internal development funding for GTx-102 or GTx-101 under its current operating plan. Accordingly, the Company determined that the remaining carrying value of the GTx-102 and GTx-101 IPR&D assets of $9,196 and $4,337, respectively, are no longer recoverable on an internal-development basis. The Company expects to recognize an impairment charge for the full remaining carrying value in the first quarter of fiscal year 2027.